Drug Resistance Among Asymptomatic Infection

Asymptomatic Infections Clinical Trial

Official title: Assessment of Drug Resistance Molecular Markers in Asymptomatic Malaria Among Migrant Workers in Myanmar

Status Completed

Clinical Trial Summary

A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.

Clinical Trial Description

Although malaria prevalence is decreasing in Myanmar, drug resistance threatens the malaria elimination by 2030 especially high risk persons including migrant population. Previous study indicated that asymptomatic malaria parasite carried drug resistance gene such as K13 mutant that is genetically responsible for artemisinin resistant falciparum malaria. These asymptomatic carries may be a source to spread the disease and it is very important to conduct the surveillance on drug resistance status among high vulnerable persons. Unfortunately, there is no study to assess the drug resistance molecular markers in asymptomatic malaria among migrant workers in Myanmar. Therefore, this study fulfills the gaps of knowledge on important of asymptomatic hidden infection exploring to formulate the recommendation for elimination of malaria in Myanmar.

In this study, asymptomatic infections are screened by rapid diagnostic test, microscopy and molecular methods. ;

Related Conditions & MeSH terms

• Asymptomatic Infections
• Communicable Diseases
• Drug Resistant Malaria
• Infection
• Malaria
• Migrant Workers

• NCT number: NCT03648411
• Study type: Observational
• Source: Department of Medical Research, Lower Myanmar
• Status: Completed
• Start date: January 12, 2019
• Completion date: May 20, 2020